Metropolitan Life Insurance Co NY Increases Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Metropolitan Life Insurance Co NY boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 112,400.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,625 shares of the medical instruments supplier’s stock after buying an additional 5,620 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in LeMaitre Vascular were worth $343,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of LMAT. Goldman Sachs Group Inc. lifted its stake in LeMaitre Vascular by 73.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 100,697 shares of the medical instruments supplier’s stock valued at $4,912,000 after buying an additional 42,591 shares in the last quarter. HRT Financial LP purchased a new stake in LeMaitre Vascular in the 1st quarter valued at approximately $208,000. Ameriprise Financial Inc. lifted its stake in LeMaitre Vascular by 25.2% in the 1st quarter. Ameriprise Financial Inc. now owns 323,879 shares of the medical instruments supplier’s stock valued at $15,794,000 after buying an additional 65,087 shares in the last quarter. Morgan Stanley lifted its stake in LeMaitre Vascular by 61.3% in the 1st quarter. Morgan Stanley now owns 302,995 shares of the medical instruments supplier’s stock valued at $14,781,000 after buying an additional 115,111 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in LeMaitre Vascular by 42.5% in the 1st quarter. D. E. Shaw & Co. Inc. now owns 18,631 shares of the medical instruments supplier’s stock valued at $909,000 after buying an additional 5,555 shares in the last quarter. 81.39% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director David B. Roberts sold 19,712 shares of the company’s stock in a transaction on Wednesday, November 3rd. The stock was sold at an average price of $52.24, for a total transaction of $1,029,754.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

A number of brokerages have weighed in on LMAT. Roth Capital increased their price target on LeMaitre Vascular from $55.00 to $58.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 3rd. Barrington Research increased their price target on LeMaitre Vascular from $59.00 to $64.00 and gave the stock an “outperform” rating in a research note on Friday, July 30th. Zacks Investment Research lowered LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Tuesday, November 2nd. Finally, Jefferies Financial Group began coverage on LeMaitre Vascular in a research note on Thursday, September 16th. They set a “buy” rating and a $70.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $63.80.

LMAT stock opened at $50.88 on Thursday. The firm has a market cap of $1.11 billion, a P/E ratio of 38.55, a price-to-earnings-growth ratio of 4.03 and a beta of 1.30. The business’s fifty day moving average price is $54.40. LeMaitre Vascular, Inc. has a 52 week low of $34.23 and a 52 week high of $64.50.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 28th. The medical instruments supplier reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.03). The firm had revenue of $38.37 million for the quarter, compared to analyst estimates of $39.05 million. LeMaitre Vascular had a return on equity of 14.15% and a net margin of 18.21%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.37 earnings per share. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.29 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 2nd. Stockholders of record on Friday, November 19th will be issued a dividend of $0.11 per share. The ex-dividend date is Thursday, November 18th. This represents a $0.44 dividend on an annualized basis and a dividend yield of 0.86%. LeMaitre Vascular’s payout ratio is 33.33%.

About LeMaitre Vascular

LeMaitre Vascular, Inc engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.

Read More: What is the definition of arbitrage?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.